Shanghai Serum Bio-Technology (688163.SH) recorded a net profit of 45.3956 million yuan in 2024, an increase of 17.08% year-on-year.

Shanghai Serum Bio-Technology (688163.SH) released its 2024 annual performance report. The company's total operating income in 2024 was 195 million yuan, an increase of 2.51% year-on-year. Net profit attributable to owners of the parent company was 45.3956 million yuan, an increase of 17.08% year-on-year. Net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 29.355 million yuan, an increase of 22.30% year-on-year. Basic earnings per share were 0.42 yuan. During the reporting period, the company focused on its core business, further expanded its market, increased product sales and production volume, and saw a steady increase in operating income with a certain degree of gross profit margin recovery. Due to the high base of R&D expenses in the previous year, R&D expenses in this reporting period decreased year-on-year.